Nikos Pekiaridis | Nurphoto | Getty images
Thursday, the reworked government panel of Robert F. Kennedy Jr. CrippleCatter to protect infants from the syncytial respiratory virus, a temporary stay for public health officials and businesses concerned by the vaccination policy of the Secretary of Health and Social Services.
The group, called the advisory committee on vaccination practices, or ACIP, also voted unanimously to include Merck’s shooting in the list of government vaccinations recommended by childhood which receive wide insurance coverage.
Votes in favor of the injectable, ENPLSIA antibodies are a sigh of relief for drug manufacturers and the medical community after Kennedy earlier this month emptied the panel and has made replacements, some of which are well-known vaccine criticisms.
The panel will allow the company to launch the shot before the RSV season which generally starts around fall and winter and lasts in spring. The Enfonsie, recommended for infants during their first RSV season, will compete in head with a rival shot of Sanofi And Astrazeneca called Beyfortus.
Both are preventive monoclonal antibodies, which provide antibodies directly in the blood circulation to provide immediate protection. But everyone targets a different part of the virus, which makes it difficult to compare them directly.
The RSV causes thousands of deaths among older Americans and hundreds of deaths among infants each year, and complications from the virus are the main cause of hospitalization in newborns. In A Middle -to -end test at the influenza, the shooting reduced RSV hospitalizations by more than 84% and reduced hospitalizations due to the drop in respiratory infections by 90% compared to a placebo in infants for five months.
Two of the criticisms of the vaccines on the panel, Retsef Levi and Vicky Pebsworth, voted against the recommendation of Merck’s Shot and questioned his security throughout the meeting.
But some other members underlined the security of Merck shooting, which obtained approval from the Food and Drug Administration earlier this month.
“These are really remarkable products. They are safe and they are effective, and I do not think there are other data that must be presented,” said Dr Cody Meissner, member, professor of pediatrics at the Geisel School of Medicine in Dartmouth.
The ACIPS working group has spent a lot of time, the FDA has spent a lot of efforts to examine security and efficiency, and it is simply not a problem here, “said Meissner, who also held consulting positions at the CDC and the FDA.
Other experts from Reunion, who are not members of the committee, agreed.
“This is a huge advance for the medical sciences, and I urge the committee to approve and adopt this resolution so that we can continue to protect our children and keep them healthy,” said Dr. Jason Goldman, president of the American College of Physicians.
Levi said he had voted against the blow because he thought he was not “ready to be administered to all healthy babies. He added:” I think we should adopt a more precautionary approach on this subject. “”
Voting specifically recommends a dose of Merck shooting for infants aged 8 months or less born during or entering their first RSV season.